Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
Rev. bras. ginecol. obstet; 46 (), 2024
Abstract Objective Neoadjuvant chemotherapy (NACT) has become the standard of care for patients with triple-negative breast cancer (TNBC) with tumors > 1 cm or positive axillary nodes. Pathologic complete response (pCR) has been used as an endpoint to select patients for treatment scaling. This stud...